New post-hoc analysis examined daily oral orforglipron in adults over 65 with obesity, with or without diabetes

A new analysis presented at the European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12–15 May) examined daily oral ...
Medscape

Low PSA Alone May Not Fully Predict Survival in Advanced Prostate Cancer

A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.
Healio

Post hoc analysis finds quick response to Xiidra

A post hoc analysis of phase 3 pivotal data demonstrated sustained symptom improvements in patients with dry eye disease who ...
Medscape

Did Hyperglycemia Affect Inavolisib-Efficacy in Patients With Breast Cancer?

Exploratory data show inavolisib benefits persist regardless of hyperglycemia in PIK3CA-mutated breast cancer, with ...

Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint ...

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the publication of a post-hoc win ...
Nasdaq

Amicus Therapeutics Publishes Positive Post-Hoc Analysis of Cipaglucosidase Alfa-Atga + Miglustat in Late-Onset Pompe Disease

Amicus Therapeutics has released a post-hoc analysis from the PROPEL study, published in Muscle and Nerve, which evaluated the efficacy of cipaglucosidase alfa-atga combined with miglustat (cipa+mig) ...
Nasdaq

Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures

BOSTON and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (Rapport or the Company), a clinical-stage biotechnology company dedicated to the discovery and ...
EurekAlert!

New post-hoc analysis shows patients whose clinicians had access to GeneSight results for depression treatment are more likely to feel better sooner

SALT LAKE CITY, Oct. 30, 2025 – Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis of the Precision Medicine in ...
Business Wire

Endeavor BioMedicines Presents New Clinical Findings From Post Hoc Analysis of Phase 2a Clinical Trial Evaluating ENV-101 in Patients with Idiopathic Pulmonary Fibrosis

SAN DIEGO--(BUSINESS WIRE)--Endeavor BioMedicines (“Endeavor”), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients ...
The American Journal of Managed Care

Post Hoc Analysis Findings Offer Guidance for Anemia Management in Myelofibrosis: Pankit Vachhani, MD

A post hoc analysis of the phase 3b JUMP trial supports the real-world use of ruxolitinib with anemia supportive care to maintain dosing and clinical outcomes in patients with myelofibrosis, offering ...